Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BATTLE Trial: Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions

Trial Profile

BATTLE Trial: Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Arteriosclerosis; Peripheral artery restenosis; Peripheral vascular disorders
  • Focus Therapeutic Use
  • Acronyms BATTLE
  • Most Recent Events

    • 07 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Mar 2016 Planned End Date changed from 1 Mar 2018 to 1 Sep 2018, as reported by ClinicalTrials.gov.
    • 07 Mar 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top